Safety & Availability (Biologics)
Image
This webpage was developed to provide the public with important information about the safety and availability of biological products.
Safety communications older than 2 years are available on FDA Archive.
Biologics Safety and Availability Communications
- 2021 Safety and Availability Communications
- 2020 Safety and Availability Communications
- 2019 Safety and Availability Communications
- 2018 Safety and Availability Communications
- 2017 Safety and Availability Communications - ARCHIVED
- 2016 Safety and Availability Communications - ARCHIVED
- 2015 Safety and Availability Communications - ARCHIVED
- 2014 Safety and Availability Communications - ARCHIVED
- 2013 Safety and Availability Communications - ARCHIVED
Related Information
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program
- Letters to Industry / Healthcare Providers / Clinical Investigators - ARCHIVED
- Bovine Spongiform Encephalopathy (BSE)
- FDA's Sentinel Initiative
- CBER Biologics Effectiveness and Safety (BEST) System
Sub-Topic Paragraphs
Paragraph Header
Follow CBER
Paragraph Header
Follow CBER
Contact Point
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3103
Silver Spring, MD 20993-0002
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3103
Silver Spring, MD 20993-0002
(800) 835-4709
(240) 402-8010
Hours Available
Food and Drug Administration
Food and Drug Administration
White Oak Campus
White Oak Campus
10903 New Hampshire Ave
Silver Spring, MD 20993
United States
For Updates on Twitter follow
Contact Point Twitter
@fdacber
The latest information from the Center for Biologics Evaluation and Research.